Back to search

France· FR:64232374

DEFANYL 100 mg, comprimé

A amoxapine product containing amoxapine, registered in France by EISAI SAS. The same ATC class is registered in 4 of our 19 countries.

ATC N06AA17

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedDEFANYL 100 mg, compriméATCN06AA17REGISTER NO.FR:64232374PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Amoxapine is registered in 4 of 19 countries.

Countries holding a registration under ATC N06AA17 (amoxapine), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 2 of them publish a price we can compare per daily dose

Amoxapine · ATC N06AA17

4 / 19 countries

  • Franceprice
  • Japan
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
AMOXAPINE
Manufacturer
EISAI SAS
Country
France (FR)
ATC code
N06AA17
ATC class
Amoxapine
Defined daily dose
0.15 g, O
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400933338602
    plaquette(s) PVC-Aluminium de 30 comprimé(s)

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

305 interactions on record for amoxapine.

Graded by severity as the source publishes them — 65 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Amoxapine · interactions on record

305 records

  • 65 severe
  • 223 moderate
  • 16 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • MetoclopramideA03FA01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Amoxapine in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All amoxapine products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/46336384-5fa6-4d73-99e7-16ad568646e9
GET /v1/drugs/46336384-5fa6-4d73-99e7-16ad568646e9?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "64232374",
  "date_amm": "1986-03-14",
  "type_amm": "Procédure nationale",
  "numero_ue": null,
  "substance": "AMOXAPINE",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation archivée",
  "statut_bdm": "Warning disponibilité",
  "forme_pharmaceutique": "comprimé",
  "voies_administration": "orale",
  "etat_commercialisation": "Non commercialisée",
  "surveillance_renforcee": "Non"
}

See everything about amoxapine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.